Floatz logo

Tocilizumab

Locally Advanced Bladder Carcinoma

M.D. Anderson Cancer Centermonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

121 Active assets in the Locally Advanced Bladder Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
G1 Therapeutics, Inc.
Phase 3BBB
TRASTUZUMAB
NKGen Biotech, Inc.
Phase 2BB
Carboplatin
G1 Therapeutics, Inc.
Phase 3BB
Pembrolizumab
Essen Biotech
Phase 3BB
Cyclophosphamide
Beijing Biotech
Phase 3BB

View all 50 →

Same molecule, other indications

Tocilizumab is also rated in:

rheumatoid arthritisDormant
BB
Indicative ·
66 / 100
View asset →
COVID-19Dormant
BB
Indicative ·
65 / 100
View asset →
acute chest syndromeDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →